<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337944</url>
  </required_header>
  <id_info>
    <org_study_id>19.382</org_study_id>
    <nct_id>NCT04337944</nct_id>
  </id_info>
  <brief_title>Endoscopic Assisted Anterior Hyaloid Peeling in Boston Type 1 Keratoprosthesis (KPro-HP-Endo)</brief_title>
  <acronym>KPro-HP-Endo</acronym>
  <official_title>Impact of Endoscopic Assisted Anterior Hyaloid Peeling in Boston Type 1 Keratoprosthesis in Reducing Postoperative Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Common complications of the Boston keratoprosthesis type 1 (KPro) surgery include
      retroprosthetic membrane formation, glaucoma, and retinal detachment. Often pars plana
      vitrectomy (PPV) is performed at the same time as KPro surgery for different indications. It
      has been shown to reduce postoperative complications in comparison to when it is performed
      after the KPro surgery. Patients who receive a complete PPV with peeling of the anterior
      hyaloid membrane have a lower incidence of retroprosthetic membrane formation and less vision
      loss due to glaucoma when compared to patients with partial PPV or anterior vitrectomy.
      During a complete PPV, peeling of the anterior hyaloid membrane is a difficult step because
      visualisation is poor, but it can be improved using endoscopy. The investigators suggest that
      peeling of the anterior hyaloid membrane assisted by endoscopy during KPro surgery would
      decrease postoperative complications in comparison to a PPV done after KPro surgery and
      without endoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Boston keratoprosthesis type 1 (KPro) surgery is the most common corneal graft and is used to
      restore vision in patients with high risk of failure with traditional penetrating
      keratoplasty. Common complications of KPro surgery include retroprosthetic membrane formation
      behind the backplate of the KPro. Glaucoma is the most common threat to vision rehabilitation
      in patients with KPro. Glaucoma is often present before surgery and progresses after KPro,
      seven times faster than in patients with only glaucoma. Retinal detachment is a common
      posterior segment complication that arises post-KPro and can lead to a serious loss of
      vision. Pars plana vitrectomy (PPV) is the standard treatment for patients with vitreoretinal
      diseases and opacities. PPV can include peeling of the anterior hyaloid membrane to ensure
      total resection of the vitreous body. PPV allows for example for retroprosthetic membrane
      excision, installation or revision of a glaucoma drainage device, or repair of retinal
      detachment. Often PPV is performed at the same time as KPro surgery for different
      indications. It has been shown to reduce postoperative complications in comparison to when it
      is performed after the KPro surgery. Patients who receive a complete PPV with peeling of the
      anterior hyaloid membrane have a lower incidence of retroprosthetic membrane formation and
      less vision loss due to glaucoma when compared to patients with partial PPV or anterior
      vitrectomy. Combined surgeries of KPro and PPV offer a complete evaluation of the optic nerve
      and of the retina, which would not be possible otherwise. During a complete PPV, peeling of
      the anterior hyaloid membrane is a difficult step because visualisation is poor, especially
      with a KPro in place. Visualisation can be improved using endoscopy to visualize the inside
      of the eye over 360 degrees. The investigators suggest that peeling of the anterior hyaloid
      membrane assisted by endoscopy during KPro surgery would decrease postoperative complications
      in comparison to a PPV done after KPro surgery and without endoscopy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Interventional prospective study on patients receiving a Boston keratoprosthesis type 1, using a retrospective group as the control group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of retroprosthetic membrane formation</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of postoperative retroprosthetic membrane formation behind the backplate of the Boston keratoprosthesis. Retroprosthetic membrane formation is diagnosed by the investigator using an examination of the anterior chamber performed at the slit-lamp.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of retinal detachment</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of postoperative retinal detachment. Retinal detachment is diagnosed by the investigator using a dilated fundus (retinal) examination performed at the slit-lamp.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of glaucoma development</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of development or progression of glaucoma, determined based on intraocular pressure increase of &gt; 21 mmHg, increase of glaucoma medications, optic nerve excavation progression, or need to undergo glaucoma filtration surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with visual acuity better than 20/200</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients with visual acuity better than 20/200 after surgery. The visual acuity is measured using the Snellen chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Change of visual acuity compared between before and after surgery. The visual acuity is measured using the Snellen chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to retroprosthetic membrane formation after surgery</measure>
    <time_frame>12 months</time_frame>
    <description>Time to retroprosthetic membrane formation, calculated in months from the time of the surgery. Retroprosthetic membrane formation behind the backplate of the Boston keratoprosthesis is diagnosed by the investigator using an examination of the anterior chamber performed at the slit-lamp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to retinal detachment after surgery</measure>
    <time_frame>12 months</time_frame>
    <description>Time to retinal detachment, calculated in months from the time of the surgery. Retinal detachment is diagnosed by the investigator using a dilated fundus (retinal) examination performed at the slit-lamp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants requiring glaucoma surgery</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of participants requiring glaucoma surgery (including glaucoma drainage device, trabeculectomy or cyclophotocoagulation) after the Boston keratoprothesis surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with visual field loss of 30% or more</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients with visual field loss of 30% or more, measured using the automated Humphrey 24-2 visual field. The loss of 30% or more of visual field is calculated using the first two postoperative tests as a reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with thinning of the nerve fiber layer</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients with thinning of the nerve fiber layer, determined by Spectral Domain Optical Coherence Tomography (SD-OCT) in average and for each of the four quadrants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Boston keratoprosthesis complications</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of Boston keratoprosthesis complications. Complications from the Boston keratoprosthesis include: corneal melt, retroprosthetic membrane formation, retinal detachment, cystic macular edema, extrusion, hypotony, choroidal hemorrhage.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Corneal Transplantation</condition>
  <condition>Glaucoma and Ocular Hypertension</condition>
  <condition>Postoperative Complications</condition>
  <condition>Vitrectomy</condition>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>Patients with KPro, PPV, and endoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy</intervention_name>
    <description>Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.</description>
    <arm_group_label>Patients with KPro, PPV, and endoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged from 18 to 80 years old

          -  Informed consent

          -  Boston keratoprosthesis candidate

          -  Pars plana vitrectomy candidate

          -  Ability to be followed for the duration of the study

        Exclusion Criteria:

          -  Aged less than 18 or more than 80 years old

          -  Inability to give informed consent

          -  Repeat Boston keratoprosthesis

          -  Repeat pars plana vitrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona Harissi-Dagher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Catherine Tessier, M.Sc.</last_name>
    <phone>1-514-890-8000</phone>
    <phone_ext>11550</phone_ext>
    <email>marie-catherine.tessier.chum@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique Geoffrion, B.Sc.</last_name>
    <phone>1-514-890-8000</phone>
    <phone_ext>11550</phone_ext>
    <email>dominique.geoffrion@mail.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Catherine Tessier, M.Sc.</last_name>
      <phone>1-514-890-8000</phone>
      <phone_ext>11550</phone_ext>
      <email>marie-catherine.tessier.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Mona Harissi-Dagher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Szigiato AA, Bostan C, Nayman T, Harissi-Dagher M. Long-term visual outcomes of the Boston type I keratoprosthesis in Canada. Br J Ophthalmol. 2020 Feb 17. pii: bjophthalmol-2019-315345. doi: 10.1136/bjophthalmol-2019-315345. [Epub ahead of print]</citation>
    <PMID>32066560</PMID>
  </reference>
  <reference>
    <citation>Wang Q, Harissi-Dagher M. Characteristics and management of patients with Boston type 1 keratoprosthesis explantation--the University of Montreal Hospital Center experience. Am J Ophthalmol. 2014 Dec;158(6):1297-1304.e1. doi: 10.1016/j.ajo.2014.08.037. Epub 2014 Aug 28.</citation>
    <PMID>25174898</PMID>
  </reference>
  <reference>
    <citation>Harissi-Dagher M, Durr GM, Biernacki K, Sebag M, Rhéaume MA. Pars plana vitrectomy through the Boston Keratoprosthesis type 1. Eye (Lond). 2013 Jun;27(6):767-9. doi: 10.1038/eye.2013.58. Epub 2013 Apr 12.</citation>
    <PMID>23579405</PMID>
  </reference>
  <reference>
    <citation>Robert MC, Pomerleau V, Harissi-Dagher M. Complications associated with Boston keratoprosthesis type 1 and glaucoma drainage devices. Br J Ophthalmol. 2013 May;97(5):573-7. doi: 10.1136/bjophthalmol-2012-302770. Epub 2013 Feb 23.</citation>
    <PMID>23435225</PMID>
  </reference>
  <reference>
    <citation>Moussally K, Harissi-Dagher M. Long-term complications associated with glaucoma drainage devices and Boston keratoprosthesis. Am J Ophthalmol. 2011 Nov;152(5):883-4; author reply 884-5. doi: 10.1016/j.ajo.2011.07.014.</citation>
    <PMID>22017851</PMID>
  </reference>
  <reference>
    <citation>Talajic JC, Agoumi Y, Gagné S, Moussally K, Harissi-Dagher M. Prevalence, progression, and impact of glaucoma on vision after Boston type 1 keratoprosthesis surgery. Am J Ophthalmol. 2012 Feb;153(2):267-274.e1. doi: 10.1016/j.ajo.2011.07.022. Epub 2011 Oct 7.</citation>
    <PMID>21982110</PMID>
  </reference>
  <reference>
    <citation>Dohlman CH, Zhou C, Lei F, Cade F, Regatieri CV, Črnej A, Dohlman JG, Shen LQ, Paschalis EI. Glaucoma After Corneal Trauma or Surgery-A Rapid, Inflammatory, IOP-Independent Pathway. Cornea. 2019 Dec;38(12):1589-1594. doi: 10.1097/ICO.0000000000002106.</citation>
    <PMID>31453878</PMID>
  </reference>
  <reference>
    <citation>Crnej A, Paschalis EI, Salvador-Culla B, Tauber A, Drnovsek-Olup B, Shen LQ, Dohlman CH. Glaucoma progression and role of glaucoma surgery in patients with Boston keratoprosthesis. Cornea. 2014 Apr;33(4):349-54. doi: 10.1097/ICO.0000000000000067.</citation>
    <PMID>24531120</PMID>
  </reference>
  <reference>
    <citation>Khan BF, Harissi-Dagher M, Khan DM, Dohlman CH. Advances in Boston keratoprosthesis: enhancing retention and prevention of infection and inflammation. Int Ophthalmol Clin. 2007 Spring;47(2):61-71. Review.</citation>
    <PMID>17450007</PMID>
  </reference>
  <reference>
    <citation>Boscher C, Kuhn F. Endoscopic evaluation and dissection of the anterior vitreous base. Ophthalmic Res. 2015;53(2):90-9. doi: 10.1159/000370032. Epub 2015 Jan 27.</citation>
    <PMID>25633467</PMID>
  </reference>
  <reference>
    <citation>Modjtahedi BS, Eliott D. Vitreoretinal complications of the Boston Keratoprosthesis. Semin Ophthalmol. 2014 Sep-Nov;29(5-6):338-48. doi: 10.3109/08820538.2014.959204. Review.</citation>
    <PMID>25325859</PMID>
  </reference>
  <reference>
    <citation>Yu YZ, Zou YP, Zou XL. Endoscopy-assisted vitrectomy in the anterior vitreous. Int J Ophthalmol. 2018 Mar 18;11(3):506-511. doi: 10.18240/ijo.2018.03.23. eCollection 2018. Review.</citation>
    <PMID>29600187</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Boston keratoprosthesis type 1</keyword>
  <keyword>Pars plana vitrectomy</keyword>
  <keyword>Endoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

